- Title: Subtitle
- OS-059 Volixibat for the treatment of cholestatic pruritus in primary biliary cholangitis: an adaptive, randomized, placebo-controlled phase 2b trial (VANTAGE): 28-week interim results
- Creators
- Michael HeneghanMitchell ShiffmanDebra WeinsteinVictor Ankoma-SeyProf Nimer AssyDian-Jung ChiangMaurizia BrunettoJonel TrebickaCurtis FreedlandLisa FormanAntonio SanchezAlan BonderQiang CaiHrishikesh SamantNatasha Von RoennJohn EatonNyingi KemmerJiten KothadiaChirag PatelSuresh VenkatachalapathyEhud ZigmondEli ZuckermanRoberto J. FirpiTh. Till WissniowskiBrian BorgHesham Elsaid ElgouhariManish ThaparNeha AgrawalJustin BoikeFrançois HabersetzerAna LleoAlexandre LouvetRoger McCorryGuy NeffColeman I. SmithAlbert TranRaffaella ViganòFrank Erhard UschnerMaximilian Joseph BrolYooyun ChungIlkay ErgencTiago NunesHallam GugelmannJayshree KrishnaswamiWill GarnerJoanne QuanPamela VigKris V. Kowdley
- Resource Type
- Abstract
- Publication Details
- Journal of hepatology, Vol.82(Supplement 1), pp.S44-S45
- DOI
- 10.1016/S0168-8278(25)00374-5
- ISSN
- 0168-8278
- Language
- English
- Date published
- 05/2025
- Academic Unit
- Gastroenterology and Hepatology; Internal Medicine
- Record Identifier
- 9984823067202771
Abstract
OS-059 Volixibat for the treatment of cholestatic pruritus in primary biliary cholangitis: an adaptive, randomized, placebo-controlled phase 2b trial (VANTAGE): 28-week interim results
Journal of hepatology, Vol.82(Supplement 1), pp.S44-S45
05/2025
DOI: 10.1016/S0168-8278(25)00374-5
Details
Metrics
1 Record Views